Liu Chia-Lin, Chen Su-Feng, Wu Min-Zu, Jao Shu-Wen, Lin Yaoh-Shiang, Yang Chin-Yuh, Lee Tsai-Yu, Wen Lian-Wu, Lan Guo-Lun, Nieh Shin
Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan.
Department of Dental Hygiene, China Medical University, Taichung, Taiwan.
Oncotarget. 2016 Mar 22;7(12):14279-90. doi: 10.18632/oncotarget.7306.
Treatment failure followed by relapse and metastasis in patients with non-small cell lung cancer is often the result of acquired resistance to cisplatin-based chemotherapy. A cancer stem cell (CSC)-mediated anti-apoptotic phenomenon is responsible for the development of drug resistance. The underlying molecular mechanism related to cisplatin resistance is still controversial, and a new strategy is needed to counteract cisplatin resistance. We used a nonadhesive culture system to generate drug-resistant spheres (DRSPs) derived from cisplatin-resistant H23 lung cancer cells. The expressions of drug-resistance genes, properties of CSCs, and markers of anti-apoptotic proteins were compared between control cells and DRSPs. DRSPs exhibited upregulation of cisplatin resistance-related genes. Gradual morphological alterations showing epithelial-to-mesenchymal transition phenomenon and increased invasion and migration abilities were seen during induction of DRSPs. Compared with control cells, DRSPs displayed increased CSC and anti-apoptotic properties, greater resistance to cisplatin, and overexpression of p-Hsp27 via activation of p38 MAPK signaling. Knockdown of Hsp27 or p38 decreased cisplatin resistance and increased apoptosis in DRSPs. Clinical studies confirmed that the expression of p-Hsp27 was closely associated with prognosis. Overexpression of p-Hsp27 was usually detected in advanced-stage patients with lung cancer and indicated short survival.
DRSPs were useful for investigating drug resistance and may provide a practical model for studying the crucial role of p-Hsp27 in the p38 MAPK-Hsp27 axis in CSC-mediated cisplatin resistance. Targeting this axis using siRNA Hsp27 may provide a treatment strategy to improve prognosis and prolong survival in lung cancer patients.
非小细胞肺癌患者治疗失败后出现复发和转移,通常是对基于顺铂的化疗产生获得性耐药的结果。癌症干细胞(CSC)介导的抗凋亡现象是耐药性产生的原因。与顺铂耐药相关的潜在分子机制仍存在争议,需要一种新的策略来对抗顺铂耐药。我们使用非粘附培养系统从顺铂耐药的H23肺癌细胞中生成耐药球体(DRSPs)。比较了对照细胞和DRSPs之间耐药基因的表达、CSC的特性以及抗凋亡蛋白的标志物。DRSPs表现出顺铂耐药相关基因的上调。在DRSPs诱导过程中,观察到逐渐的形态学改变,呈现上皮-间质转化现象,侵袭和迁移能力增强。与对照细胞相比,DRSPs表现出增加的CSC和抗凋亡特性,对顺铂的耐药性更强,并且通过激活p38 MAPK信号通路使p-Hsp27过表达。敲低Hsp27或p38可降低DRSPs的顺铂耐药性并增加其凋亡。临床研究证实p-Hsp27的表达与预后密切相关。p-Hsp27的过表达通常在晚期肺癌患者中检测到,提示生存期短。
DRSPs有助于研究耐药性,可能为研究p-Hsp27在CSC介导的顺铂耐药的p38 MAPK-Hsp-27轴中的关键作用提供一个实用模型。使用siRNA Hsp27靶向该轴可能为改善肺癌患者的预后和延长生存期提供一种治疗策略。